Celldex Therapeutics (NASDAQ:CLDX) Posts Earnings Results, Beats Expectations By $0.02 EPS

Celldex Therapeutics (NASDAQ:CLDX) released its earnings results on Thursday. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02, Zacks reports. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million.

Celldex Therapeutics Stock Performance

Shares of CLDX stock opened at $20.57 on Friday. Celldex Therapeutics has a 52-week low of $19.83 and a 52-week high of $53.18. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -8.00 and a beta of 1.60. The firm has a fifty day moving average of $23.86 and a 200-day moving average of $28.95.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday. Finally, UBS Group initiated coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective on the stock. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.50.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.